Safe and efficient in vivo hematopoietic stem cell transduction in nonhuman primates using HDAd5/35++ vectors-Reference-Cited by-同舟云学术

Safe and efficient in vivo hematopoietic stem cell transduction in nonhuman primates using HDAd5/35++ vectors

Published:2022-03 Issue: Volume:24 Page:127-141
ISSN:2329-0501
Container-title:Molecular Therapy - Methods & Clinical Development
language:en
Short-container-title:Molecular Therapy - Methods & Clinical Development

Author:

Li Chang,Wang Hongjie,Gil Sucheol,Germond Audrey,Fountain Connie,Baldessari Audrey,Kim Jiho^ORCID,Liu Zhinan,Georgakopoulou Aphrodite^ORCID,Radtke Stefan^ORCID,Raskó Tamás,Pande Amit,Chiang Christina,Chin Eli^ORCID,Yannaki Evangelia^ORCID,Izsvák Zsuzsanna^ORCID,Papayannopoulou Thalia^ORCID,Kiem Hans-Peter^ORCID,Lieber André^ORCID

Funder

NIH

Bill & Melinda Gates Foundation

Publisher

Elsevier BV

Subject

Genetics,Molecular Biology,Molecular Medicine

Reference68 articles.

1. Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives;Naldini;EMBO Mol. Med.,2019

2. Gene therapy in patients with transfusion-dependent beta-thalassemia;Thompson;N. Engl. J. Med.,2018

3. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ss-thalassemia;Marktel;Nat. Med.,2019

4. CRISPR-Cas9 gene editing for Sickle cell disease and beta-thalassemia;Frangoul;N. Engl. J. Med.,2021

5. Prophylactic in vivo hematopoietic stem cell gene therapy with an immune checkpoint inhibitor reverses tumor growth in syngeneic mouse tumor models;Li;Cancer Res.,2020

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Auto-expansion of in vivo HDAd-transduced hematopoietic stem cells by constitutive expression of tHMGA2;Molecular Therapy - Methods & Clinical Development;2024-09

2. A simplified G-CSF–free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model;Blood Advances;2024-07-31

3. Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells;Nature Nanotechnology;2024-05-23

4. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1;Scientific Reports;2024-05-13

5. Targeted, safe, and efficient gene delivery to human hematopoietic stem and progenitor cells in vivo using the engineered AVID adenovirus vector platform;Molecular Therapy;2024-01